Latest Exelixis Stories
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 31, 2014 /PRNewswire/ -- Today, Analysts Review released its research
LONDON, April 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
SAN FRANCISCO, Aug.
BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ -- Change Change Change at Change at on a constant on a constant Q2 reported exchange reported exchange 2009 basis rates H1 2009 basis rates ------- --------- -------- ------- ------- -------...
Exelixis, a development-stage biotechnology company, has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to discover novel therapies targeted against the liver X receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.